435 related articles for article (PubMed ID: 28270621)
1. Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells.
Bierie B; Pierce SE; Kroeger C; Stover DG; Pattabiraman DR; Thiru P; Liu Donaher J; Reinhardt F; Chaffer CL; Keckesova Z; Weinberg RA
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):E2337-E2346. PubMed ID: 28270621
[TBL] [Abstract][Full Text] [Related]
2. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
3. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Masugi Y; Yamazaki K; Emoto K; Effendi K; Tsujikawa H; Kitago M; Itano O; Kitagawa Y; Sakamoto M
Lab Invest; 2015 Mar; 95(3):308-19. PubMed ID: 25599535
[TBL] [Abstract][Full Text] [Related]
6. The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.
Mooney SM; Talebian V; Jolly MK; Jia D; Gromala M; Levine H; McConkey BJ
J Cell Biochem; 2017 Sep; 118(9):2559-2570. PubMed ID: 28266048
[TBL] [Abstract][Full Text] [Related]
7. ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts.
Sung JS; Kang CW; Kang S; Jang Y; Chae YC; Kim BG; Cho NH
Oncogene; 2020 Jan; 39(3):664-676. PubMed ID: 31534187
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits.
Ma B; Zhang L; Zou Y; He R; Wu Q; Han C; Zhang B
J Exp Clin Cancer Res; 2019 Jan; 38(1):23. PubMed ID: 30658712
[TBL] [Abstract][Full Text] [Related]
9. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
[TBL] [Abstract][Full Text] [Related]
10. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
11. STAT3 Targets
Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
[TBL] [Abstract][Full Text] [Related]
12. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
13. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
Wang K; Zou P; Zhu X; Zhang T
Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
[TBL] [Abstract][Full Text] [Related]
14. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.
Alkatout I; Wiedermann M; Bauer M; Wenners A; Jonat W; Klapper W
Exp Mol Pathol; 2013 Feb; 94(1):168-73. PubMed ID: 22985790
[TBL] [Abstract][Full Text] [Related]
15. Study on inhibition of Britannin on triple-negative breast carcinoma through degrading ZEB1 proteins.
Lu H; Wu Z; Wang Y; Zhao D; Zhang B; Hong M
Phytomedicine; 2022 Sep; 104():154291. PubMed ID: 35839735
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide binding of transcription factor ZEB1 in triple-negative breast cancer cells.
Maturi V; Enroth S; Heldin CH; Moustakas A
J Cell Physiol; 2018 Oct; 233(10):7113-7127. PubMed ID: 29744893
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
18. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
Damiano V; Brisotto G; Borgna S; di Gennaro A; Armellin M; Perin T; Guardascione M; Maestro R; Santarosa M
Genes Chromosomes Cancer; 2017 Feb; 56(2):147-158. PubMed ID: 27717206
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
